Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission

Century Therapeutics Inc. (NASDAQ:IPSC) is one of the best fast growing penny stocks to buy according to analysts. On January 20, Piper Sandler increased its price target for Century Therapeutics to $4 from $2 with an Overweight rating, citing the company’s plan to submit an IND for CNTY-813 this year and deliver initial data by 2027. Additionally, the firm highlighted Century’s strong financial position, estimating a pro forma cash balance of approximately $267 million that is expected to fund operations through Q1 2029.

Earlier on January 8, Clear Street analyst Bill Maughan reduced the price target for Century Therapeutics Inc. (NASDAQ:IPSC) to $6.60 from $8 while keeping a Buy rating. Maughan noted that a recent private placement extends the company’s cash runway into Q1 2029, providing sufficient time to realize the full potential of its lead asset, CNTY-813, without requiring immediate additional capital.

While the price target was lowered by Clear Street to account for dilution from the capital raise, the firm also emphasized that this was partially offset by an increased likelihood of pipeline success and higher projected peak sales.

Century Therapeutics Inc. (NASDAQ:IPSC) is a clinical-stage biotechnology company that develops allogeneic cell therapies for the treatment of solid tumors, hematological malignancies, and autoimmune diseases.

While we acknowledge the potential of IPSC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.